US FDA's CRL delays 'FAME' and fortune for Alimera, pSivida
This article was originally published in Scrip
Executive Summary
The US FDA was anything but jolly this holiday season, instead playing "Bad Santa" by doling out lumps of coal to several drug makers in the form of complete response letters (CRLs), with Alimera Sciences and its partner pSivida among the companies burned by the agency.